FDA OKs Lymphoma 'Breakthrough' Drug

Thursday, 14 Nov 2013 08:15 AM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson & Johnson and Pharmacyclics Inc, marking the second drug that received the FDA's new breakthrough therapy designation to gain approval.

The drug, to be sold under the brand name, Imbruvica, and known chemically as ibrutinib, was approved to treat mantle cell lymphoma in patients who have received prior treatment with at least one other medicine, such as Celgene Corp's Revlimid.
 
Mantle cell lymphoma represents about 6 percent of non-Hodgkin lymphoma cases in the United States and has typically spread to lymph nodes, bone marrow and other organs by the time it is diagnosed, the Food and Drug Administration said.

Obamacare: Massive New Rules Revealed for 2013

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Did FDA Food-Dragging Delay New Diet Pill Approval?

Friday, 19 Sep 2014 17:24 PM

The FDA's approval of the new diet pill Contrave could have come more than three years ago, an agency critic argues. . . .

Simple Test Detects Alzheimer's Early

Friday, 19 Sep 2014 17:18 PM

York University researchers have devised a simple test that combines thinking and movement can help to detect a person's . . .

Exercise Makes Chemo More Effective: Study

Friday, 19 Sep 2014 17:12 PM

Exercise has been shown to boost the effectiveness of chemotherapy in new research that suggests patients who work out m . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved